ESMO Breast 2023 | Addressing the underrepresentation of ILC in clinical trials

Karen Van Baelen, MD, KU Leuven, Leuven, Belgium, discusses the steps she believes should be taken in order to improve the inclusion of patients with invasive lobular breast cancer (ILC) in more clinical trials. Dr Van Baelen highlights the necessity to redefine how metastatic progression is measured within these trials in order to account for the differing metastatic patterns and non-measure disease that is often characteristic of ILC. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.